Pharmacokinetics Efficacy & Safety of Novel Selective-dose Cannabis Inhaler in Chronic Pain Patients скачать в хорошем качестве

Pharmacokinetics Efficacy & Safety of Novel Selective-dose Cannabis Inhaler in Chronic Pain Patients

Syqe’s 2020 clinical study examined the safety and effectiveness of the SyqeAir Inhaler for patients with chronic neuropathic pain. Conducted in a real-world hospital setting, the study evaluated the impact of metered and low doses of medical cannabis (Δ9-THC) delivered via the SyqeAir Inhaler, focusing on pain reduction, functional improvement, and safety outcomes. Determining an accurate, consistent dose of medical cannabis remains a significant clinical challenge. Our research aimed to demonstrate that the SyqeAir Inhaler enables safe, uniform, and controlled administration of medical cannabis, resulting in meaningful pain relief with a low incidence of adverse events. Listen to this short podcast (16 minutes) as we discuss this groundbreaking study's key findings and clinical significance. Read the full article here: https://onlinelibrary.wiley.com/doi/f... Visit our website: https://www.syqe.com/ In accordance with the approved indications in Protocol 106. Subject to the recommendation of a physician and a license for use in accordance with the requirements of the law. Clinically-validated. This is not a medical recommendation.